Literature DB >> 3132938

Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods.

A Närvänen1, M Korkolainen, S Kontio, J Suni, S Turtianen, P Partanen, J Soos, A Vaheri, M L Huhtala.   

Abstract

A synthetic pentadecapeptide (A15; env residues 599-613: SGKLICTTAVPWNAS), derived from a hydrophobic region in the transmembrane protein gp41 of HIV-1 and comprising a highly immunoreactive antigenic site in eliciting antibody responses during HIV-1 infection in humans, was used to purify, by affinity, the corresponding anti-peptide antibodies from HIV-1-infected patient sera. The purified antibodies to peptide A15 reacted specifically with the peptide in EIA, but not in whole virus EIA. These antibodies were immunoreactive with the corresponding peptide-albumin conjugates in immunoblotting but not with gp41 molecules. The results suggest that the peptide A15 sequence is not exposed in intact gp41, but will be exposed and is antigenic in the course of HIV-1 infection in humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132938     DOI: 10.1097/00002030-198804000-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.

Authors:  V Boyer; H Broly; S Souche; P Madaule; J Rossier; D Zagury; C Desgranges
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus.

Authors:  T Hovi; M Roivainen
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

4.  Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody.

Authors:  T H Bugge; B O Lindhardt; L L Hansen; P Kusk; E Hulgaard; K Holmbäck; P J Klasse; J Zeuthen; K Ulrich
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors:  J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans.

Authors:  K Holmbäck; P Kusk; E F Hulgaard; T H Bugge; E Scheibel; B O Lindhardt
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.

Authors:  M Ohlin; P A Broliden; L Danielsson; B Wahren; J Rosen; M Jondal; C A Borrebaeck
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.